Despite having multiple risk factors for poor prognosis, our patients exhibited a 1-year RFS rate similar to that reported in the CheckMate 577 study [6] and similar to that in a phase II trial investigating the efficacy of adjuvant durvalumab, a monoclonal antibody against PD-L1, in patients with locally advanced EAC or GEJ adenocarcinoma after neoadjuvant CRT and surgery [17]. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.